Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: Recent results and future prospects

Leukemia

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Renner, C ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Immunotoxins; Monoclonal antibodies; Non hodgkin's lymphoma; Surface antigens

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; IDIOTYPIC ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RICIN A;

ANTIBODY SPECIFICITY; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG TARGETING; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0031011793     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 405-407.
2. Reisfeld RA. Monoclonal antibodies in cancer immunotherapy. Clin Lab Med 1992; 12: 201-216.
3. Grossbard ML, Press OW, Appelbaum FR, Bernstein IW, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
4. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber H, Pichlmaier H, Hirche H, Suggisch P, Witte J, German Cancer Aid 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-1183.